Consolidated Statements of Cash Flows (USD $) In Thousands	6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010
Operating Activities
Net income	$ 5,181	$ 7,246
Adjustments to reconcile net income to net cash flows provided by operating activities:
Change in deferred policy acquisition costs	1,996	(889)
Depreciation and amortization	3,827	2,117
Deferred income tax expense	2,739	942
Net realized (gains) losses	(1,227)	(49)
Stock-based compensation expense	401	72
Amortization of premiums and discounts on investments	239	147
Non-controlling interest	(172)	53
Changes in operating assets and liabilities, net of the effects of acquisitions
Accrued investment income	(106)	72
Other receivables	1,435	(3,360)
Reinsurance recoverables	(1,257)	11,296
Other assets	898	(2,887)
Unpaid claims	(1,815)	(3,136)
Unearned premiums	(6,892)	(11,573)
Accrued expenses and accounts payable	(4,514)	2,298
Deferred revenue	(1,738)	0
Net cash flows (used in) provided by operating activities	(1,005)	2,349
Investing activities
Proceeds from maturities of available-for-sale investments	5,021	6,372
Proceeds from sales of available-for-sale investments	22,520	4,299
Proceeds from maturities of short term investments	100	50
Purchases of available-for-sale investments	(29,470)	(10,262)
Purchases of property and equipment	(5,044)	(4,192)
Net (paid) for acquisitions of subsidiaries, net of cash received	(40,752)	(11,704)
Proceeds from notes receivable	83	425
Change in restricted cash	4,163	(5,097)
Net cash flows used in investing activities	(43,379)	(20,109)
Financing activities
Payments on notes payable	(42,963)	(18,509)
Proceeds from notes payable	75,450	25,531
Capitalized closing costs for notes payable	(2,395)	0
Payments for intial public offering costs	(827)	0
Payments on redeemable preferred stock	(10,690)	(100)
Net proceeds from exercise of stock options	400	0
Net cash flows provided by financing activities	18,975	6,922
Net decrease in cash and cash equivalents	(25,409)	(10,838)
Cash and cash equivalents, beginning of period	43,389	29,940
Cash and cash equivalents, end of period	$ 17,980	$ 19,102